The Claim
Patients with homozygous familial hypercholesterolemia (HoFH) who have an LDLR-defective/defective genotype exhibit a more favorable response to PCSK9 inhibitors, achieving a mean low-density lipoprotein cholesterol (LDL-C) reduction of -19.6% (standard deviation 12.1%), suggesting that residual LDL receptor function contributes to partial therapeutic efficacy.
What the research says
Challenges is higher
Challenge is ahead, but a single strong supporting study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with a rare genetic cholesterol disorder who still have a little bit of working cholesterol-cleaning system in their body tend to respond better to a certain type of cholesterol drug, lowering their bad cholesterol by about 20% on average.
See the scientific wording
Patients with homozygous familial hypercholesterolemia (HoFH) and LDLR-defective/defective genotype have a more favorable response to PCSK9 inhibitors, with a mean LDL-C reduction of -19.6% (SD 12.1%), indicating residual LDL receptor function enables partial therapeutic benefit.
What the research says
1 studyThe study looked at the same cholesterol drugs in the same group of patients, but found they barely helped—much less than the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.